<DOC>
	<DOCNO>NCT02716961</DOCNO>
	<brief_summary>It still challenge urologic surgeon prevent post transurethral resection bladder tumor ( TURBT ) recurrence moderate-high risk non-muscle invasive bladder tumor . Adjuvant chemotherapy standard treatment local progressive bladder tumor , contain mainstream GC treatment scheme . It common observe clinically moderate-high risk NMIBC recurrence routine intravesical instillation.Systematic chemotherapy eliminate remain tumor cell especially mucosa basal cell improve prognosis patient . Our clinical trial aim investigate whether utilization combination GC treatment scheme epirubicin instillation would decrease recurrence moderate-high risk NMIBC .</brief_summary>
	<brief_title>Transurethral Resection Bladder Tumor ( TURBT ) Combined With Adjuvant Intravenous GC Chemotherapy Non-muscle-invasive Bladder Cancer</brief_title>
	<detailed_description>Prevention post-transurethral resection bladder tumor ( TURBT ) recurrence moderate-high risk non-muscle invasive bladder cancer ( NMIBC ) still difficult problem . NMIBC classify low , moderate high risk patient . Moderate-high risk NMIBC contain multiple , recurrent , II-III grade , tumor diameter &gt; 3cm , invasive submucosa associate carcinoma situ . For patient , matter treatment conduct , example , exchange instillation drug , increase medicine dose , append adjuvant drug prolong instillation time , would improve prognosis patient . Adjuvant chemotherapy standard treatment local progressive bladder tumor , contain mainstream GC treatment scheme . For muscle invasive bladder cancer patient , radical cystectomy neoadjuvant chemotherapy improve patient ' tumor grade increase overall survival disease specific survival rate.Systematic chemotherapy eliminate remain tumor cell especially mucosa basal cell improve prognosis patient . Our clinical trial aim investigate whether utilization combination GC treatment scheme epirubicin instillation would decrease recurrence moderate-high risk NMIBC . In addition , also would like investigate improvement life quality TURBT moderate-high risk NMIBC .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1. moderatehigh risk nonmuscle invasive bladder cancer patient : Multiple , recurrent , IIIII grade , tumor diameter &gt; 3cm , invasive submucosa , associate carcinoma situ . 2 . Normal liver renal function . 1 . Liver renal function deficiency ( GFR &lt; 60ml/min*kg , ALT、AST &gt; 1.5*normal ) , lung function deficiency , heart failure , acute myocardial infarction , severe infection trauma , major surgery clinical hypotension anaerobic condition . 2 . Attending drug experiment . 3 . Performance status , ZubrodECOGWHO , ZPS≥2 . 4 . Pregnant . 5 . Bone marrow transplantation , severe leukopenia , associate severe infection injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>